skip to the content

Clinical Trials

Systemic Lupus Erythematosus Study

A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)

Protocol ID

07-02-283

Protocol Description

Systemic lupus erythematosus (SLE) is a chronic (long term) autoimmune disease of unknown cause. SLE can affect different people in different ways, but it oftne involves chronic inflammation and organs can be damaged. The ways in which this happens are becoming clearer to doctors, and research into SLE suggests that the expermintal drug, atacicept, might play a role in controlling the symptoms and signs of the disease.

The purpose of this research study is to evaluate how well atacicept works, how safe it is, and to identify the best dose of atacicept for SLE. In addition, the study will measure the effects of atacicept on some substances in the blood which measure the "activity" or severity of SLE. This study will also look at possible effects of atacicept on the progression of SLE.

Eligibility Criteria

Patients with systemic lupus erythematosus

Primary Investigator(s)

  • Cynthia Aranow, MD

Contact Information

Sanita Kandasami
(516) 562-240
skandasami@nshs.edu

Last Update

April 5, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Lupus:
top
top